These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 25641747)

  • 1. Cardiovascular safety pharmacology profile of etamicastat, a novel peripheral selective dopamine-β-hydroxylase inhibitor.
    Pires NM; Loureiro AI; Igreja B; Lacroix P; Soares-da-Silva P
    Eur J Pharmacol; 2015 Mar; 750():98-107. PubMed ID: 25641747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and tolerability of etamicastat following single and repeated administration in elderly versus young healthy male subjects: an open-label, single-center, parallel-group study.
    Nunes T; Rocha JF; Vaz-da-Silva M; Falcão A; Almeida L; Soares-da-Silva P
    Clin Ther; 2011 Jun; 33(6):776-91. PubMed ID: 21704242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Etamicastat, a novel dopamine β-hydroxylase inhibitor: tolerability, pharmacokinetics, and pharmacodynamics in patients with hypertension.
    Almeida L; Nunes T; Costa R; Rocha JF; Vaz-da-Silva M; Soares-da-Silva P
    Clin Ther; 2013 Dec; 35(12):1983-96. PubMed ID: 24296323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sustained high blood pressure reduction with etamicastat, a peripheral selective dopamine β-hydroxylase inhibitor.
    Igreja B; Wright LC; Soares-da-Silva P
    J Am Soc Hypertens; 2016 Mar; 10(3):207-16. PubMed ID: 26803288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of food on the pharmacokinetic profile of etamicastat (BIA 5-453).
    Vaz-da-Silva M; Nunes T; Rocha JF; Falcão A; Almeida L; Soares-da-Silva P
    Drugs R D; 2011; 11(2):127-36. PubMed ID: 21548660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Etamicastat, a new dopamine-ß-hydroxylase inhibitor, pharmacodynamics and metabolism in rat.
    Loureiro AI; Bonifácio MJ; Fernandes-Lopes C; Igreja B; Wright LC; Soares-da-Silva P
    Eur J Pharmacol; 2014 Oct; 740():285-94. PubMed ID: 25058908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, tolerability, and pharmacokinetics of etamicastat, a novel dopamine-β-hydroxylase inhibitor, in a rising multiple-dose study in young healthy subjects.
    Nunes T; Rocha JF; Vaz-da-Silva M; Igreja B; Wright LC; Falcão A; Almeida L; Soares-da-Silva P
    Drugs R D; 2010; 10(4):225-42. PubMed ID: 21171669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-dose tolerability, pharmacokinetics, and pharmacodynamics of etamicastat (BIA 5-453), a new dopamine β-hydroxylase inhibitor, in healthy subjects.
    Rocha JF; Vaz-Da-Silva M; Nunes T; Igreja B; Loureiro AI; Bonifácio MJ; Wright LC; Falcão A; Almeida L; Soares-Da-Silva P
    J Clin Pharmacol; 2012 Feb; 52(2):156-70. PubMed ID: 21343348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N-acetylation of etamicastat, a reversible dopamine-β-hydroxylase inhibitor.
    Loureiro AI; Fernandes-Lopes C; Bonifácio MJ; Wright LC; Soares-da-Silva P
    Drug Metab Dispos; 2013 Dec; 41(12):2081-6. PubMed ID: 24013186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blood pressure decrease in spontaneously hypertensive rats folowing renal denervation or dopamine β-hydroxylase inhibition with etamicastat.
    Pires NM; Igreja B; Moura E; Wright LC; Serrão MP; Soares-da-Silva P
    Hypertens Res; 2015 Sep; 38(9):605-12. PubMed ID: 25854989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. QTc shortening with a new investigational cancer drug: a brief case study.
    Himmel HM; Hoffmann M
    J Pharmacol Toxicol Methods; 2010; 62(1):72-81. PubMed ID: 20570746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of P-glycoprotein and permeability upon the brain distribution and pharmacodynamics of etamicastat: a comparison with nepicastat.
    Loureiro AI; Bonifácio MJ; Fernandes-Lopes C; Pires N; Igreja B; Wright LC; Soares-da-Silva P
    Xenobiotica; 2015; 45(9):828-39. PubMed ID: 25915108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of the interaction of the novel antihypertensive etamicastat with human dopamine-β-hydroxylase: comparison with nepicastat.
    Bonifácio MJ; Sousa F; Neves M; Palma N; Igreja B; Pires NM; Wright LC; Soares-da-Silva P
    Eur J Pharmacol; 2015 Mar; 751():50-8. PubMed ID: 25641750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety pharmacology assessment of drug-induced QT-prolongation in dogs with reduced repolarization reserve.
    Vormberge T; Hoffmann M; Himmel H
    J Pharmacol Toxicol Methods; 2006; 54(2):130-40. PubMed ID: 16757186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A highly sensitive canine telemetry model for detection of QT interval prolongation: studies with moxifloxacin, haloperidol and MK-499.
    Chaves AA; Zingaro GJ; Yordy MA; Bustard KA; O'Sullivan S; Galijatovic-Idrizbegovic A; Schuck H; Christian DB; Hoe CM; Briscoe RJ
    J Pharmacol Toxicol Methods; 2007; 56(2):103-14. PubMed ID: 17643323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of nortriptyline on QT prolongation: a safety pharmacology study.
    Jeon SH; Jaekal J; Lee SH; Choi BH; Kim KS; Jeong HS; Han SY; Kim EJ
    Hum Exp Toxicol; 2011 Oct; 30(10):1649-56. PubMed ID: 21262863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of methylphenidate hydrochloride on the cardiovascular system in vivo and in vitro: a safety pharmacology study.
    Wakamatsu A; Nomura S; Tate Y; Shimizu S; Harada Y
    J Pharmacol Toxicol Methods; 2009; 59(3):128-34. PubMed ID: 19281853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distribution and pharmacokinetics of etamicastat and its N-acetylated metabolite (BIA 5-961) in dog and monkey.
    Loureiro AI; Soares-da-Silva P
    Xenobiotica; 2015; 45(10):903-11. PubMed ID: 25869244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suitability of commonly used excipients for electrophysiological in-vitro safety pharmacology assessment of effects on hERG potassium current and on rabbit Purkinje fiber action potential.
    Himmel HM
    J Pharmacol Toxicol Methods; 2007; 56(2):145-58. PubMed ID: 17590357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Action potential experiments complete hERG assay and QT-interval measurements in cardiac preclinical studies.
    Ducroq J; Printemps R; Guilbot S; Gardette J; Salvetat C; Le Grand M
    J Pharmacol Toxicol Methods; 2007; 56(2):159-70. PubMed ID: 17604185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.